跳至主要内容
临床试验/NCT04865510
NCT04865510已完成不适用

Citrate Versus Heparin in Continuous Renal Replacement Therapy : Effect on Cardiovascular System and Clot Circuit in Critically Ill Patients

Bangkok Metropolitan Administration Medical College and Vajira Hospital2 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2019年2月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
41
试验地点
2
主要终点
Cardiac output

研究概览

简要总结

This study is a prospective, multicenter, open-label randomized trial comparing regional citrate anticoagulation (RCA) with heparin-free protocol. The function mode was continuous venovenous hemodiafiltration (CVVHDF) in post-dilution mode. The investigators measured hemodynamic changes at certain time points after starting CRRT (0, 6, 12, 24, 48, 72 hr).Levels of inflammatory cytokine (IL-1β, IL-6, IL-8, IL-10 and TNF-ɑ) were measured at day 1 and day 3

详细描述

Twenty patients were randomized into heparin group and 11 patients were in citrate group. The cardiac performance were not significantly different between 2 groups at every time point. The inflammatory cytokines declined similarly in both treatment arms. The maximum filter survivial time was longer in a RCA group but not reach statistically significant (44.64±26.56 hr vs p=0.693 in citrate and heparin free group respectively).There was no serious side effects dung both treatment arm even in the group of liver dysfunction patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
Single (Care Provider)

盲法说明

systemic random sampling (block of four). Group A was the citrate group while group B was heparin- free method.

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • need for CRRT,
  • no contraindication to CRRT

排除标准

  • patients with previous history of chronic kidney disease (CKD) (baseline serum creatinine > 2 mg/dL (male) or > 1.5 mg/dL (female)
  • history of renal transplantation
  • known pregnancy
  • previous dialysis within 30 days
  • severe liver disease
  • end stage heart disease or untreatable malignancy
  • moribund patients with expected survival less than 30 days
  • previous use of heparin or other anticoagulant, antiplatelet within 7 day except use for deep vein thrombosis
  • active bleeding at the time of enrollment and/or severe coagulopathy
  • receiving blood or blood components prior to enrollment
  • hemoglobin less than 7.5 g/dL and/or platelet count less than 100,000/mm3
  • previous underlying clotting disorders such as hypercoagulable state
  • severe malnutrition (Body mass index (BMI ) less than 18)
  • underwent CRRT for other reasons besides acute kidney injury (AKI)

结局指标

主要结局

Cardiac output

时间窗: 72 hour

cm3/min

Systemic vascular resistance

时间窗: 72 hour

mmHg⋅min⋅mL-1

Cardiac index

时间窗: 72 hour

L/min/m2

Systemic vascular resistance index

时间窗: 72 hour

dynes · sec/cm5/m2

次要结局

  • Filter life span(through study completion,an aveage of 72 hours)
  • Changes of IL-6(day 1,day 3)
  • Renal survival(28 day)
  • Changes of IL-10(day 1,day 3)
  • Mortality(28 day)
  • Changes of IL-1β(day 1,day 3)
  • Changes of IL-8(day 1,day 3)
  • Changes of TNF-ɑ(day 1,day 3)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Thananda Trakarnvanich

Associate Professor

Bangkok Metropolitan Administration Medical College and Vajira Hospital

研究点 (2)

Loading locations...

相似试验